NDAORALTABLET
Approved
Apr 2016
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
4
Data completeness
7/8 — Comprehensive
DESCOVY (emtricitabine and tenofovir alafenamide) by Gilead Sciences is nucleoside reverse transcriptase inhibitors [moa]. Approved for human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor [epc]. First approved in 2016.
Drug data last refreshed 13h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DESCOVY is a fixed-dose oral tablet combining emtricitabine and tenofovir alafenamide, nucleoside reverse transcriptase inhibitors used to treat HIV-1 infection. It works by blocking reverse transcriptase enzyme activity to suppress viral replication. The drug is indicated for HIV treatment and represents a modernized backbone option with improved renal and bone safety compared to older tenofovir formulations.
$590MPart D
PeakStable
9.9 years to LOEDESCOVY remains in peak lifecycle with sustained $590M annual spending, though it faces significant intra-company cannibalization from higher-revenue Biktarvy, suggesting smaller dedicated team size relative to flagship products.
Mechanism of Action
Nucleoside Reverse Transcriptase Inhibitors
Pharmacologic Class:
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (4)
REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE
Started Jun 2026
200 enrolled
HIV -1 InfectionHIV (Human Immunodeficiency Virus)HIV+1 more
Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIV
Started Mar 2024
26 enrolled
HIV I InfectionCardiovascular Risk FactorLipid Metabolism Disorders
An Italian Observation of Antiretroviral Treatment in Participants Taking Darunavir/ Cobicistat Plus Emtricitabine and Tenofovir Alafenamide Fumarate
Started Jun 2018
246 enrolled
Human Immunodeficiency Virus (HIV)
Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection
Started Sep 2016
5,399 enrolled
Pre-Exposure Prophylaxis of HIV-1 Infection
Worked on DESCOVY at Gilead Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.